Trial Profile

A Phase 1, First-in-human, Randomized, Participant- and Investigator-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of ETH47 in Healthy Participants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Jul 2025 Status changed from recruiting to completed.
30 Jan 2025 According to Ethris media release, Based on the encouraging Phase 1 results, Ethris filed a Clinical Trial Application (CTA) for a Phase 2a rhinovirus challenge study in asthma patients, planned to begin in Q2 2025.
30 Jan 2025 According to Ethris media release,company announced promising topline data from this trial at the mRNA-Based Therapeutics Summit Europe in Frankfurt, Germany.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com